The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC

Published Online: 12:24 AM, Sun June 2, 2019


Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer. 

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.